Competitor Analysis: Targeted Therapy of Diabetes

Date: April 1, 2011
Pages: 114
Price:
US$ 1,735.00
License [?]:
Publisher: La Merie Publishing
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C2D9A236FDCEN
Leaflet:

Download PDF Leaflet

Competitor Analysis: Targeted Therapy of Diabetes
Product description

The present Competitive Intelligence Report about Targeted Therapy of Diabetes provides a competitor evaluation in the field of novel molecules being developed for treatment of type 1 and 2 diabetes as of April 2011. Major pharmacologic approaches include insulin, PPAR agonists, DPP-IV inhibitors, GLP-1 analogs and SGLT inhibitors. Furthermore, emerging approaches for diabetes therapy are reported including glucokinase activators and 11beta-HSD1 inhibitors. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of currently active projects in research and development of novel molecules for treatment of type 1 and 2 diabetes. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

Insulin
  • Rec Human Insulin for Injection (2nd Generation)
  • Biosimilar Rec Human Insulin for Injection (2nd Generation) in
  • Regulated Markets
  • Rhu Insulin (2nd Generation) in Off-Patent Countries: China
  • Rhu Insulin (2nd Generation) in Off-Patent Countries: Russia
  • Rhu Insulin (2nd Generation) in Off-Patent Countries: India
  • Rhu Insulin (2nd Generation) in Off-Patent Countries: Others
  • Modern Insulin Analogs (3rd Generation) for Injection
  • Modern Insulin Analogs (3rd Generation) in Less-Regulated Markets
  • Tailored and Novel Insulin Analogs (4th Generation) for
  • Injection
  • Human Insulin with Drug Delivery for Injection
  • Other Long-Acting Insulin for Injection
  • Transgenic Human Insulin for Injection
  • Insulin/GLP-1 Combination Products
  • Inhaled Insulin
  • Oral Insulin
  • Transdermal Insulin
  • Others

PPAR Agonists
  • PPAR alpha Agonists
  • PPAR gamma Agonists / Insulin Sensitizer
  • PPAR alpha and gamma Agonists
  • PPAR delta Agonists
  • PPAR delta and gamma Agonists
  • PPAR alpha and delta Agonists
  • PPAR pan Agonists (alpha, gamma and delta)
  • Unspecified PPAR Agonists

Dipeptidyl peptidase-IV (DPP-IV) Inhibitors
  • GLP-1 Receptor Agonists
  • GLP-1 Analogs with Daily SC Injections
  • GLP-1 Analogs with Once Weekly SC Injections
  • GLP-1 Analogs with Bi-Weekly or Monthly SC Injections
  • Other GLP-1 Analogs for SC Injections
  • GLP-1 Analogs in Drug Delivery Formulations/Devices for
  • Parenteral Administration
  • GLP-1 Analogs in Drug Delivery Formulations for Oral
  • Administration
  • Oral Small Molecule GLP-1 Receptor Agonists
  • Dual Target GLP-1 Receptor Agonists / Combination Products
  • GLP-1 Analogs in Other, Non-Diabetes Indications

Sodium-Dependent Glucose Co-Transporter 2 (SGLT-2) Inhibitors

11beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors

Glucokinase Activators (GKA)

Other Emerging Diabetes Drugs
  • Adenosine Monophosphate Activated Protein Kinase (AMPK) Agonists
  • Sirtuin (SIRT) Activators
  • Protein tyrosine Phosphatase-1B (PTP-1B) Inhibitors
  • Glucagon Receptor (GCGR) Antagonists
  • Glucocorticoid Receptor (GCGR) Antagonists
  • Novel Insulin Sensitizers
  • G-Protein Coupled Receptor 119 (GPR119) Agonists
  • Other Drugs Augmenting GLP-1 Secretion: GPR40, GPR120 & TGR5 Agonists
  • Other Glucometabolic Approaches
  • Acyl-CoA:Diacylglycerol Acyltransferase1 (DGAT1) Inhibitors
  • Other Metabolic Approaches
  • FGF-21-Receptor Agonists
  • Anti-Inflammatory Approaches
  • Induction of Immune Tolerance
  • Pancreatic Beta Cell Protection & Regeneration
  • Pancreatic Islet Cell Transplantation
  • Various Antidiabetic Approaches

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Ask Your Question

Competitor Analysis: Targeted Therapy of Diabetes
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: